Catalyst Pharmaceutical Partners, Inc. Reports Successful Completion Of Type B Breakthrough Therapy Meeting With FDA On Firdapse Tablets Development Program

Published: Jan 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORAL GABLES, Fla., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) about Firdapseā„¢ tablets (Amifampridine), its lead product being evaluated for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).

Help employers find you! Check out all the jobs and post your resume.

Back to news